Celldex Therapeutics
Clinical trials sponsored by Celldex Therapeutics, explained in plain language.
-
New hope for chronic hive sufferers: drug shows promise in major trial
Disease control OngoingThis study tests a new drug called barzolvolimab for people with chronic spontaneous urticaria (long-term hives and itching) that antihistamines don't control. About 963 adults will receive either the drug or a placebo to see if it reduces hives and itching over 12 weeks. The goa…
Phase: PHASE3 • Sponsor: Celldex Therapeutics • Aim: Disease control
Last updated May 07, 2026 18:40 UTC
-
New drug shows promise for relieving unbearable itch in rare skin disease
Symptom relief OngoingThis study tests an experimental drug called barzolvolimab in 140 adults with prurigo nodularis, a condition that causes intense itching and hard bumps on the skin. The main goal is to see if the drug can significantly reduce itch severity over 12 weeks compared to a placebo. Par…
Phase: PHASE2 • Sponsor: Celldex Therapeutics • Aim: Symptom relief
Last updated May 17, 2026 05:18 UTC
-
New eczema drug shows promise in reducing itch and rash
Symptom relief OngoingThis study tests an investigational drug called barzolvolimab in adults with moderate to severe atopic dermatitis (eczema). About 131 participants will receive either a low dose, high dose, or placebo to see if it reduces itching and clears skin over 16 weeks. The goal is to find…
Phase: PHASE2 • Sponsor: Celldex Therapeutics • Aim: Symptom relief
Last updated May 17, 2026 05:07 UTC
-
New hope for chronic hives sufferers: experimental drug targets itch and welts
Symptom relief OngoingThis study tests an experimental drug called barzolvolimab in about 976 adults with chronic spontaneous urticaria (CSU) — a condition causing daily hives and itching for at least 6 months. Participants must still have symptoms despite taking standard antihistamines. The study com…
Phase: PHASE3 • Sponsor: Celldex Therapeutics • Aim: Symptom relief
Last updated May 14, 2026 12:07 UTC